REGENXBIO Inc. Available-for-sale Securities, Amortized Cost Basis
REGENXBIO Inc. (RGNX) had Available-for-sale Securities, Amortized Cost Basis of $164.38 million as of 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-05-08
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $164.38M.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $130.02M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $131.38M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $151.06M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-03-31 | $164.38M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $130.02M 10-Q · filed 2018-05-08 |
| 2017-09-30 | $131.38M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $151.06M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $127.64M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $133.72M 10-K · filed 2018-03-06 |
| 2016-09-30 | $155.90M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $168.11M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $172.82M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $162.97M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |